Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type.

Conclusions: Preclinical in-vitro and in-vivo studies identified ADI-PEG20 as a potential therapy for patients with rare ovarian cancers including SCCOHT.
PMID: 32409304 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 13, 2020 Category: Cancer & Oncology Authors: Ji JX, Cochrane DR, Tessier-Cloutier B, Chen SY, Ho G, Pathak KV, Alcazar IN, Farnell D, Leung S, Cheng A, Chow C, Colborne S, Negri GL, Kommoss F, Karnezis A, Morin GB, McAlpine JN, Gilks B, Weissman BE, Trent JM, Hoang L, Pirrotte P, Wang Y, Huntsman DG Tags: Clin Cancer Res Source Type: research